Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

INTRODUCTION: In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal dominant polycystic kidney disease (...

Descripción completa

Detalles Bibliográficos
Autores principales: Devuyst, Olivier, Chapman, Arlene B., Shoaf, Susan E., Czerwiec, Frank S., Blais, Jaime D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733681/
https://www.ncbi.nlm.nih.gov/pubmed/29270521
http://dx.doi.org/10.1016/j.ekir.2017.07.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733681/
https://www.ncbi.nlm.nih.gov/pubmed/29270521
http://dx.doi.org/10.1016/j.ekir.2017.07.004

Ejemplares similares